TABLE 3-1 Global Distribution of Influenza Vaccine, 2000–2003

WHO Region Total Doses Distributed (000s)
2000 2001 2002 2003
Europe 93,004 99,094 103,824 102,891
      Western Europe 65,130 67,864 72,812 76,523
      Central and Eastern Europe 27,874 31,230 31,012 26,368
Americas 104,593 114,389 122,348 123,578
      Canada 11,900 10,600 9,700 11,100
      United States 68,000 78,345 82,705 84,913*
      Mexico, Central and South America 24,693 25,444 29,943 27,565
Western Pacific 29,916 39,424 41,795 61,189
      Australia 3,415 3,632 4,087 4,357
      Japan 12,491 17,440 20,802 29,253
      New Zealand 646 627 668 715
      Other countries 13,364 17,725 16,238 26,864
Southeast Asia 82 95 134 253
Eastern Mediterranean 1,043 1,201 1,163 1,540
Africa 2,291 2,530 1,298 1,230
GLOBAL TOTAL 230,929 256,733 270,562 291,979*
*

The data for the United States do not include doses of cold-adapted, live-attenuated trivalent influenza vaccine distributed by MedImmune. In 2003, MedImmune produced ~4–5 million doses of CAIV-T and distributed ~830,000 doses, but only ~250,000 doses were actually sold.

The data for the United States do not include doses of cold-adapted, live-attenuated trivalent influenza vaccine distributed by MedImmune. In 2003, MedImmune produced ~4–5 million doses of CAIV-T and distributed ~830,000 doses, but only ~250,000 doses were actually sold.

From: 3, Toward Preparedness: Opportunities and Obstacles

Cover of The Threat of Pandemic Influenza
The Threat of Pandemic Influenza: Are We Ready? Workshop Summary.
Institute of Medicine (US) Forum on Microbial Threats; Knobler SL, Mack A, Mahmoud A, et al., editors.
Washington (DC): National Academies Press (US); 2005.
Copyright © 2005, National Academy of Sciences.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.